Breakthrough:
The World's First
Triple-Agonist
Weight Loss Protocol.

The ideal entry point for new patients. Even at this introductory dose, Retatrutide begins activating all three receptors simultaneously — patients typically notice reduced appetite and improved energy within the first week. Clinician-supervised with 24-hour review. The safest way to begin the most advanced protocol available.

Step up the triple-pathway signal. At 2mg, appetite suppression noticeably strengthens and the metabolic rate boost from glucagon activation becomes more pronounced. Most patients begin reporting visible changes in body composition by week 4–6 at this dose. Provider-supervised for your safety.

Where the real transformation accelerates. At 4mg, all three receptor pathways operate at meaningful clinical levels — GLP-1 suppresses appetite, GIP improves fat metabolism, and glucagon drives your resting metabolic rate upward. Patients frequently report dramatic reductions in cravings and sustained energy throughout the day.

High-efficacy protocol approaching Phase 2 trial dosing levels. At 8mg, the compounding effect of triple-agonist action becomes fully realized — appetite is near-silent, visceral fat loss accelerates, and metabolic markers improve measurably. This is the dose range where SURMOUNT-comparable results begin to emerge. ⚡ Limited availability.

Maximum reconstituted dose — for patients committed to achieving elite results. The 12mg dose aligns with the upper range of Phase 2 trial protocols that produced the landmark 24% average body weight reduction data. Full clinician oversight included. This is the gold standard of triple-agonist therapy. Order now before summer.

Lyophilized (freeze-dried) formulation for superior long-term stability and potency. Ideal for patients who prefer enhanced shelf stability or are stocking a full protocol supply. At the 10mg dose, all three metabolic pathways are fully engaged — providing the compounding fat-loss effect that makes Retatrutide the most advanced protocol available.

Best-value lyophilized supply at a therapeutic dose with maximum stability. 20mg/3ml delivers consistent, potent triple-agonist activity per dose. Patients on this protocol report the most significant reductions in visceral abdominal fat — the metabolically dangerous fat that GLP-1 medications alone struggle to target. Clinician oversight included.

The highest-concentration lyophilized protocol — maximum potency, maximum stability, maximum results. At 30mg/3ml, this is the protocol for patients who refuse to compromise. Three metabolic pathways operating at full clinical force, backed by full provider oversight at no extra cost. Discreet shipping to all 50 states. Don't wait for summer to start.